DiaSys Corporation Signs Exclusive Agreement with Leading Clinical Diagnostics Distributor in Venezuela; Company to Immediately Commence Sales of Diagnostics Products in Country.WATERBURY, Conn. -- DiaSys Corporation, (AMEX AMEX See: American Stock Exchange : DYX DYX Dyslexia ), a global diagnostic products company, announced today that it has entered into an exclusive distribution agreement with Repreclin S.A., a large clinical diagnostics distributor based in Venezuela. Repreclin, founded in 1988, is the exclusive distributor for Beckmann Coulter Inc. and Instrumentation Laboratory SpA. The distributor will represent the complete line of DiaSys' products in Venezuela, including parasitology Parasitology The scientific study of parasites and of parasitism. Parasitism is a subdivision of symbiosis and is defined as an intimate association between an organism (parasite) and another, larger species of organism (host) upon which the parasite is workstations, consumables, urinalysis workstations, consumables, rapid tests, ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. tests and electrophoresis products. "We believe the market in Venezuela is highly attractive," said Jose Puig, DiaSys Corporation's Sales Manager for Latin America. "The reputation and strong presence that Repreclin has in the country should enable us to accelerate the development of this market, which is ideally suited for our laboratory and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. test kits. We look forward to leveraging off of their strong distribution network to rapidly grow sales in the country." Repreclin has five offices in Venezuela, with over 60 employees to support sales and technical issues. The company has distributed over 2,000 instruments in the country and is the largest clinical diagnostics distributor to the Social Security/Ministry of Health in Venezuela. The company has over 4 million parasites tested on the equipment it distributes, along with a test volume of over 8 million urine samples annually. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test kits to healthcare and veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham England. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion